REMD 477

Drug Profile

REMD 477

Alternative Names: AMG477; REMD477

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer REMD Biotherapeutics
  • Class Antihyperglycaemics
  • Mechanism of Action G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT02715193)
  • 15 Dec 2015 The US FDA approves a phase Ib trial in Type-1 diabetes mellitus
  • 01 Sep 2015 Phase-II clinical trials in Type-2 diabetes mellitus in USA (SC) (NCT0245511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top